Ledaga (chlormethine gel) for the treatment of MF-CTCL
ALLSCHWIL/BASEL, SWITZERLAND - 07 March 2017- Actelion Ltd (SIX: ATLN) announced today that the European Commission has granted marketing authorization for the use of Ledaga(R) (chlormethine gel) 160 micrograms/g for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
MF-CTCL is a rare, potentially life-threatening immune system cancer that is chronic and usually progresses slowly. The course of disease i
RelSci News & Alerts gets you: